Publications et ressources

Ce que nous mesurons, ce que nous publions

La coalition s'engage à rendre publics ses résultats. Cette page rassemble les publications issues de ses travaux, la note d'orientation et les principales sources de données citées.

Publications scientifiques

Sélection de 45 publications (2021-2026) des membres de la codirection sur l'hépatite C, le VIH, l'itinérance, l'usage de drogues et la santé des personnes migrantes. Références tirées de PubMed, avec DOI.

Codirection
Thème
45 publications affichées
  • 2026
    A cost-effectiveness analysis of a multidisciplinary model of care on hepatitis C care among people released from provincial prison in Quebec, Canada
    Weight C, Mambro A, Dussault C, … Klein MB, et coll. · Int J Drug Policy 149:105136
  • 2026
    Addressing policy barriers to scaling up needle and syringe programmes: a global call to action
    Fontaine G, Day E, Luhmann N, et coll. · Lancet Glob Health 14(1):e164-e172
  • 2026
    Effect of hepatitis C virus treatment engagement on the skin and soft tissue infections healthcare burden among people who inject drugs in Quebec, Canada: a population-based interrupted time series study
    El Sheikh MZ, Panagiotoglou D, Greenaway C, … Klein MB, et coll. · Int J Drug Policy 154:105335
  • 2026
    Gender differences in hepatitis C virus incidence in and out of opioid agonist treatment among people who inject drugs in Montréal, Canada, March 2011-March 2024
    Meconnen M, Kleiner BB, Artenie A, … Bruneau J, et coll. · Int J Drug Policy 152:105252
  • 2026
    Health care providers' perspectives on barriers and enablers to providing hepatitis C screening and treatment for immigrants in Canada: A theory-informed qualitative study
    Mortazhejri S, Greenaway C, Cooper C, et coll. · Can Liver J 9(2):261-288
  • 2026
    Hepatitis C self-testing and self-collection among people with experience in the Canadian carceral system: a qualitative study
    Barnett T, Muncaster K, Gemma O, … Fontaine G, et coll. · BMC Infect Dis 26(1)
  • 2026
    Improving the tuberculosis infection care cascade among migrants in Canada: a cost-effectiveness modelling study
    Fournier AL, Nsengiyumva NP, Jordan A, … Greenaway C, et coll. · Lancet Public Health 11(2):e92-e100
  • 2026
    Incidence of HIV and HCV Among People Who Inject Drugs in Montreal, Canada: Data From the HEPCO Longitudinal Cohort Study, 2011-2025
    Kleiner BB, Meconnen M, Azar M, … Bruneau J, et coll. · J Viral Hepat 33(6):e70185
  • 2026
    Increasing housing instability and changing spatial distribution of people who inject drugs in Montreal, Canada, 2011-2024
    Vakili F, Minoyan N, Bruneau J, et coll. · Drug Alcohol Depend 285:113201
  • 2026
    Interventions to improve testing, linkage to care, and treatment for hepatitis C infection in prison: a systematic review and meta-analysis
    Cunningham EB, Wheeler A, Hajarizadeh B, … Fontaine G, et coll. · Int J Drug Policy 149:105082
  • 2026
    Peer-led recruitment for equitable engagement of people who inject drugs: Evidence from the HEPCO cohort in Montreal, Canada
    Boisvert I, Minoyan N, Martel-Laferrière V, … Bruneau J, et coll. · Int J Drug Policy 153:105276
  • 2026
    Pharmacist-Led Hepatitis C Diagnosis and Rapid Management-In Community (PHARM-C): Results From a Phase IV Nonblinded Randomised Controlled Trial
    Biondi MJ, Capraru CI, Harper B, … Fontaine G, et coll. · J Viral Hepat 33(1):e70109
  • 2026
    Reimagining Hepatitis C Elimination: Time for Actions, Not Targets
    Klein MB, Kronfli N, Young J · J Int AIDS Soc 29(8):e70183
  • 2026
    The association between chronic pain and non-fatal overdose in people who inject drugs: Longitudinal cohort study in Montreal, Canada, 2017 to 2025
    Larney S, Zang G, Dasari H, … Bruneau J, et coll. · Addiction
  • 2025
    A pre-post study of the impact of a multidisciplinary model of care on linkage to hepatitis C care following release from prison: The Beyond Prison Walls study
    Kronfli N, Mambro A, O'Brien A, … Klein MB, et coll. · Int J Drug Policy 143:104873
  • 2025
    Estimated prevalence of hepatitis B and C among immigrants in Canada
    Campeau L, Elliott J, Williams A, … Greenaway C, et coll. · Can Commun Dis Rep 51(6-7):214-222
  • 2025
    Exploring housing instability through a gender lens among people who inject drugs in Montreal, Canada
    Vakili F, Høj SB, Minoyan N, … Bruneau J, et coll. · Drug Alcohol Rev 44(4):1138-1150
  • 2025
    Factors influencing the acceptability of hepatitis C screening among people with experience of incarceration in Quebec, Canada: A qualitative descriptive study guided by the Theoretical Domains Framework
    Mambro A, Fontaine G, Ortiz-Paredes D, et coll. · Int J Drug Policy 143:104890
  • 2025
    Harnessing telemedicine to deliver patient-centered opioid agonist treatment within a community-based harm reduction service: a mixed methods evaluation
    Høj SB, Coignard-Friedman R, Sako A, … Bruneau J, et coll. · Harm Reduct J 22(1):182
  • 2025
    Perceptions about hepatitis C and barriers and enablers to screening and treatment among Egyptian immigrants to Canada: a theory-informed qualitative study
    Mortazhejri S, Thomas IM, Patey AM, … Greenaway C, et coll. · Int J Equity Health 24(1):203
  • 2025
    Progress Toward Hepatitis C Virus Elimination among People Living with HIV-Hepatitis C Virus Coinfection in Canada
    El Sheikh MZ, Young J, Panagiotoglou D, … Klein MB, et coll. · Can Liver J 8(1):49-62
  • 2025
    Scaling up point-of-care hepatitis C testing in Canada: protocol for a multilevel implementation science study of clinical processes, barriers, facilitators and implementation strategies (SCALE-POCT study)
    Mooney M, Weight C, Biondi MJ, … Bruneau J, Fontaine G, Greenaway C, et coll. · Implement Sci Commun 7(1):10
  • 2025
    The urgent need for implementation science to achieve hepatitis C elimination
    Fontaine G, Taylor N, Bruneau J, … Greenaway C, Klein MB, et coll. · Lancet Gastroenterol Hepatol 10(6):498-502
  • 2024
    Buprenorphine/Naloxone vs Methadone for the Treatment of Opioid Use Disorder
    Nosyk B, Min JE, Homayra F, … Bruneau J, et coll. · JAMA 332(21):1822-1831
  • 2024
    Frequent Disengagement and Subsequent Mortality Among People With HIV and Hepatitis C in Canada: A Prospective Cohort Study
    Saeed S, Thomas T, Dinh DA, … Klein MB, et coll. · Open Forum Infect Dis 11(5):ofae239
  • 2024
    Hepatitis C Attributable Healthcare Costs and Mortality among Immigrants: A Population-Based Matched Cohort Study
    Erman A, Sahakyan Y, Everett K, … Greenaway C, et coll. · Can J Gastroenterol Hepatol 2024:5573068
  • 2024
    Ongoing Gaps in the Hepatitis C Care Cascade during the Direct-Acting Antiviral Era in a Large Retrospective Cohort in Canada: A Population-Based Study
    Passos-Castilho AM, Murphy DG, Blouin K, … Bruneau J, Greenaway C, Klein MB, et coll. · Viruses 16(3)
  • 2024
    Sex and gender differences in hepatitis C virus risk, prevention, and cascade of care in people who inject drugs: systematic review and meta-analysis
    Levinsson A, Zolopa C, Vakili F, … Bruneau J, et coll. · EClinicalMedicine 72:102596
  • 2024
    Using an intersectionality lens to explore barriers and enablers to hepatitis C point-of-care testing: a qualitative study among people who inject drugs and service providers
    Fontaine G, Presseau J, Bruneau J, et coll. · Int J Equity Health 23(1):124
  • 2023
    "Apparently, you can only be treated once": A qualitative study exploring perceptions of hepatitis C and access to treatment among people who inject drugs visiting a needle and syringe program
    Fontaine G, Presseau J, Bruneau J, et coll. · Int J Drug Policy 121:104124
  • 2023
    A population-based study of reported hepatitis C diagnoses from 1998 to 2018 in immigrants and nonimmigrants in Quebec, Canada
    Passos-Castilho AM, Murphy DG, Blouin K, … Bruneau J, Greenaway C, Klein MB, et coll. · J Viral Hepat 30(8):656-666
  • 2023
    Engagement with the HCV care cascade among high-risk groups: A population-based study
    Erman A, Everett K, Wong WWL, … Greenaway C, et coll. · Hepatol Commun 7(9)
  • 2023
    Incidence of HIV and hepatitis C virus among people who inject drugs, and associations with age and sex or gender: a global systematic review and meta-analysis
    Artenie A, Stone J, Fraser H, … Bruneau J, et coll. · Lancet Gastroenterol Hepatol 8(6):533-552
  • 2023
    Public health interventions, priority populations, and the impact of COVID-19 disruptions on hepatitis C elimination among people who have injected drugs in Montreal (Canada): A modeling study
    Lanièce Delaunay C, Klein MB, Godin A, et coll. · Int J Drug Policy 116:104026
  • 2023
    Recommandations pour la prise en charge de l'infection par le virus de l'hépatite C chez les usagers de drogues par injection
    Grebely J, Robaeys G, Bruggmann P, … Bruneau J, et coll. · Int J Drug Policy 111:101669
  • 2022
    Identifying barriers and enablers to opt-out hepatitis C virus screening in provincial prisons in Quebec, Canada: A multilevel, multi-theory informed qualitative study with correctional and healthcare professional stakeholders
    Ruiz AS, Fontaine G, Patey AM, et coll. · Int J Drug Policy 109:103837
  • 2022
    Improving screening and treatment for infectious diseases in migrant populations
    Greenaway C, Hargreaves S · J Travel Med 29(7)
  • 2022
    Interventions to enhance testing, linkage to care, and treatment initiation for hepatitis C virus infection: a systematic review and meta-analysis
    Cunningham EB, Wheeler A, Hajarizadeh B, … Fontaine G, et coll. · Lancet Gastroenterol Hepatol 7(5):426-445
  • 2022
    Simplifying HCV treatment: a pathway to elimination and model for delivering health care to vulnerable populations
    Klein MB · Lancet Gastroenterol Hepatol 7(4):277-279
  • 2022
    The viral hepatitis B care cascade: A population-based comparison of immigrant groups
    Yasseen AS, Kwong JC, Feld JJ, et coll. · Hepatology 75(3):673-689
  • 2022
    The war in Ukraine and refugee health care: considerations for health care providers in Canada
    Greenaway C, Fabreau G, Pottie K · CMAJ 194(26):E911-E915
  • 2021
    Can hepatitis C elimination targets be sustained among people who inject drugs post-2030?
    Lanièce Delaunay C, Godin A, Kronfli N, … Klein MB, et coll. · Int J Drug Policy 96:103343
  • 2021
    Injecting frequency trajectories and hepatitis C virus acquisition: Findings from a cohort of people who inject drugs in Montréal, Canada
    Fortier E, Høj SB, Sylvestre MP, … Bruneau J, et coll. · Int J Drug Policy 96:103439
  • 2021
    Phylogenetic Clustering among Asylum Seekers with New HIV-1 Diagnoses in Montreal, QC, Canada
    Park H, Brenner B, Ibanescu RI, … Klein MB, et coll. · Viruses 13(4)
  • 2021
    Viral hepatitis C cascade of care: A population-level comparison of immigrant and long-term residents
    Yasseen AS 3rd, Kwong JC, Feld JJ, … Greenaway C, et coll. · Liver Int 41(8):1775-1788

Travaux de la coalition à venir

  • —
    Protocole d'évaluation de l'initiative Métropoles Sans Hep C (devis mixte informé par les cadres RE-AIM et PRISM)
    Équipe d'évaluation MSHC · À venir

Dans les médias

Communiqués et articles sur la coalition et ses codirecteurs.

Ressources et sources

Documents de référence cités sur ce site et ressources des partenaires.

Vulgarisation

What does it take to eliminate hepatitis C in a city like Montreal?

Billet de CATIE (25 mai 2026) présentant la coalition, ses partenaires et les enseignements de ses travaux qualitatifs.

Données

Tout le monde compte 2025 : l'itinérance visible au Québec et son évolution

Résultats préliminaires du dénombrement du 15 avril 2025 (MSSS, 2026) : 12 077 personnes au Québec, 5 036 à Montréal.

Données

Comprendre pour transformer : agir ensemble contre l'épidémie de VIH (phase 1, rapport synthèse)

Commissaire à la santé et au bien-être, 2025. État de situation sur l'épidémie de VIH au Québec.

Cohorte

Cohorte HEPCO

Cohorte montréalaise de personnes qui s'injectent des drogues, suivie depuis plus de quinze ans pour l'incidence de l'hépatite C et du VIH.

Feuille de route

Hépatite C au Québec : feuille de route pour l'élimination

Document du CAPAHC, partenaire communautaire de la coalition.

Contact

Discuter d'un partenariat

Vous représentez un organisme communautaire, un établissement, un ministère, une fondation ou une équipe de recherche ? Écrivez-nous pour discuter d'un partenariat, d'un site de déploiement ou d'un soutien financier.

Discuter d'un partenariat

Nos engagements envers les partenaires

  • Une proposition détaillée et des lettres d'appui dans les 30 jours suivant une première rencontre.
  • Des sites ouverts aux visites.
  • Des indicateurs partagés et des résultats rendus publics chaque année.
  • Une feuille de route transférable aux autres régions du Québec.